These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 18974392)

  • 1. Quantitative live imaging of cancer and normal cells treated with Kinesin-5 inhibitors indicates significant differences in phenotypic responses and cell fate.
    Orth JD; Tang Y; Shi J; Loy CT; Amendt C; Wilm C; Zenke FT; Mitchison TJ
    Mol Cancer Ther; 2008 Nov; 7(11):3480-9. PubMed ID: 18974392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell type variation in responses to antimitotic drugs that target microtubules and kinesin-5.
    Shi J; Orth JD; Mitchison T
    Cancer Res; 2008 May; 68(9):3269-76. PubMed ID: 18451153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paclitaxel-induced aberrant mitosis and mitotic slippage efficiently lead to proliferative death irrespective of canonical apoptosis and p53.
    Yasuhira S; Shibazaki M; Nishiya M; Maesawa C
    Cell Cycle; 2016 Dec; 15(23):3268-3277. PubMed ID: 27764550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolonged mitotic arrest triggers partial activation of apoptosis, resulting in DNA damage and p53 induction.
    Orth JD; Loewer A; Lahav G; Mitchison TJ
    Mol Biol Cell; 2012 Feb; 23(4):567-76. PubMed ID: 22171325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid induction of apoptosis during Kinesin-5 inhibitor-induced mitotic arrest in HL60 cells.
    Tang Y; Orth JD; Xie T; Mitchison TJ
    Cancer Lett; 2011 Nov; 310(1):15-24. PubMed ID: 21782324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consequences of mitotic slippage for antimicrotubule drug therapy.
    Cheng B; Crasta K
    Endocr Relat Cancer; 2017 Sep; 24(9):T97-T106. PubMed ID: 28684541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitosis-targeting therapies: a troubleshooting guide.
    Doménech E; Malumbres M
    Curr Opin Pharmacol; 2013 Aug; 13(4):519-28. PubMed ID: 23583638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting mitosis for anti-cancer therapy.
    Sudakin V; Yen TJ
    BioDrugs; 2007; 21(4):225-33. PubMed ID: 17628120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitotic slippage and expression of survivin are linked to differential sensitivity of human cancer cell-lines to the Kinesin-5 inhibitor monastrol.
    Asraf H; Avunie-Masala R; Hershfinkel M; Gheber L
    PLoS One; 2015; 10(6):e0129255. PubMed ID: 26035434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-Associated Macrophages Suppress the Cytotoxic Activity of Antimitotic Agents.
    Olson OC; Kim H; Quail DF; Foley EA; Joyce JA
    Cell Rep; 2017 Apr; 19(1):101-113. PubMed ID: 28380350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preferential killing of tetraploid tumor cells by targeting the mitotic kinesin Eg5.
    Rello-Varona S; Vitale I; Kepp O; Senovilla L; Jemaá M; Métivier D; Castedo M; Kroemer G
    Cell Cycle; 2009 Apr; 8(7):1030-5. PubMed ID: 19270519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. K858, a novel inhibitor of mitotic kinesin Eg5 and antitumor agent, induces cell death in cancer cells.
    Nakai R; Iida S; Takahashi T; Tsujita T; Okamoto S; Takada C; Akasaka K; Ichikawa S; Ishida H; Kusaka H; Akinaga S; Murakata C; Honda S; Nitta M; Saya H; Yamashita Y
    Cancer Res; 2009 May; 69(9):3901-9. PubMed ID: 19351824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Universal response in the RKO colon cancer cell line to distinct antimitotic therapies.
    Lorz A; Botesteanu DA; Levy D
    Sci Rep; 2018 Jun; 8(1):8979. PubMed ID: 29895957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mcl-1 stability determines mitotic cell fate of human multiple myeloma tumor cells treated with the kinesin spindle protein inhibitor ARRY-520.
    Tunquist BJ; Woessner RD; Walker DH
    Mol Cancer Ther; 2010 Jul; 9(7):2046-56. PubMed ID: 20571074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances of kinesin motor inhibitors and their clinical progress.
    Voultsiadou A; Sarli V
    Rev Recent Clin Trials; 2011 Sep; 6(3):271-7. PubMed ID: 21682672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinesin motor proteins as targets for cancer therapy.
    Huszar D; Theoclitou ME; Skolnik J; Herbst R
    Cancer Metastasis Rev; 2009 Jun; 28(1-2):197-208. PubMed ID: 19156502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of C-terminal truncation mutation of kinesin-5 in resistance to kinesin-5 inhibitor.
    Saeki E; Yasuhira S; Shibazaki M; Tada H; Doita M; Masuda T; Maesawa C
    PLoS One; 2018; 13(12):e0209296. PubMed ID: 30557316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimitotic inhibitors.
    Campos SM; Dizon DS
    Hematol Oncol Clin North Am; 2012 Jun; 26(3):607-28, viii-ix. PubMed ID: 22520982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of chemical manipulation of mitotic arrest and slippage on cancer cell survival and proliferation.
    Riffell JL; Zimmerman C; Khong A; McHardy LM; Roberge M
    Cell Cycle; 2009 Sep; 8(18):3025-38. PubMed ID: 19713760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Development of Anti-mitotic Drugs in Cancer.
    Olziersky AM; Labidi-Galy SI
    Adv Exp Med Biol; 2017; 1002():125-152. PubMed ID: 28600785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.